Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.1925 | ||
| Change(%) | ![]() | -0.1075 | |
| Volume | 21235 | ||
| 9:13 AM - Feb 25, 2010 | |||
News
Enzon to Present at NewsMakers in the Biotech Industry Conference
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
Enzon to Present at BMO Focus on Healthcare Conference
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director

Enzon Announces IND Acceptance for its Survivin Antagonist
-- Phase I study to open for patients with solid tumors--
Enzon Discontinues Further Development of rhMBL
Enzon Concludes Tender Offer for a Portion of Its Debt
Enzon Discontinues its Plan to Spin-off its Biotechnology Business

Enzon Continues to Improve its Capital Structure
-- Company repurchased $17.5 million of its outstanding debt at a discount to par--
Enzon Discontinues Further Development of rhMBL
Enzon Announces Clinical Data From PEG-SN38 and rhMBL Studies at ASCO -- Company will host reception --
Enzon Pharmaceuticals Commences Tender Offer For a Portion of its Debt
